Edesa Biotech Inc, based in Markham, Ontario, is a clinical-stage biopharmaceutical company focused on developing treatments for inflammatory and immune-related diseases, including their lead candidate EB05 for ARDS. The company, which went public in 2008, is also advancing treatments for allergic contact dermatitis and vitiligo through its EB01 and EB06 drug candidates.
Edesa Biotech (EDSA) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Edesa Biotech's actual EPS was -$0.52, beating the estimate of -$0.59 per share, resulting in a 12.10% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
